 | You can help expand this article with text translated from the corresponding article in Italian. (December 2024)Click [show] for important translation instructions.
|
The Italian Medicines Agency (Agenzia italiana del farmaco, AIFA) is the public institution responsible for the regulatory activity of pharmaceuticals in Italy.
| International | |
|---|---|
| National | |
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
 | This article about an organisation based in Italy is a stub. You can help Wikipedia by expanding it. |
The University of Turin is a public research university in the city of Turin, in the Piedmont region of Italy. It is one of the oldest universities in Europe and continues to play an important role in research and training.
The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).
Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) with pain medication and fever reducing properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis, and primary dysmenorrhoea in adolescents and adults above 12 years old.
Marianne Merchez is a Belgian doctor from the Catholic University of Louvain and a former European Space Agency astronaut. She is certified in aerospace medicine and in industrial medicine, and she is also a professional pilot.
Narcobarbital (Pronarcon) is a barbiturate derivative developed in 1932 by Carl Heinrich Friedrich Boedecker and Heinrich Gruber Schoneberg, assignors to the firm J. D. Riedel-E. de Haën AG, Berlin, Germany. Later, in 1937, may, was patented in United States. It is an N-methylated derivative of propallylonal and has similar sedative effects. It is still used in veterinary medicine for inducing surgical anaesthesia.
The Committee for Medicinal Products for Human Use (CHMP), formerly known as the Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on all issues regarding medicinal products for human use.
Racecadotril, also known as acetorphan, is an antidiarrheal medication which acts as a peripheral enkephalinase inhibitor. Unlike other opioid medications used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect — it reduces the secretion of water and electrolytes into the intestine. It is available in France and other European countries as well as most of South America and some South East Asian countries, but not in the United States. It is sold under the tradename Hidrasec, among others. Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinases.
Tulathromycin, sold under the brand name Draxxin among others, is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs.
Firocoxib, sold under the brand names Equioxx and Previcox among others, is a nonsteroidal anti-inflammatory drug of the COX-2 inhibitor (coxib) class, approved for use in horses (Equioxx) and for use in dogs (Previcox). Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine.
Flupirtine is an aminopyridine that functions as a centrally acting non-opioid analgesic that was originally used as an analgesic for acute and chronic pain but in 2013 due to issues with liver toxicity, the European Medicines Agency restricted its use to acute pain, for no more than two weeks, and only for people who cannot use other painkillers. In March 2018, marketing authorisations for flupirtine were withdrawn following a European Medicines Agency recommendation based on the finding that the restrictions introduced in 2013 had not been sufficiently followed in clinical practice, and cases of serious liver injury still occurred including liver failure.
The Agenzia Informazioni e Sicurezza Interna, commonly known as AISI, is the domestic security agency of Italy.
Mavacoxib is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis and COVID-19.
Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).
Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.
A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.
Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.
Epoetin theta, sold under the brand name Biopoin among others, is a copy of the human hormone erythropoietin.
Bajram Begaj is an Albanian politician and military officer who has been President of Albania since 2022. Having had a long career in the Albanian army, he served as the 26th Chief of General Staff of the Albanian Armed Forces from July 2020 to June 2022. Politically independent, on 3 June 2022, Begaj was officially nominated by the governing Socialist Party as the candidate to the fourth round of the 2022 presidential election.
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.
